Sanofi hands back gene therapies to Oxford Biomedica

Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.

Novartis closes on EU approval for SMA gene therapy Zolgensm...

Novartis publishes long-term data from SMA gene therapy

Novartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting disease spinal muscular atrophy – information that will be closely

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi

First UK patients get Novartis’ Luxturna gene therapy for bl...

Inborn Errors of Metabolism Drug Development Summit 2020

Inborn Errors of Metabolism Summit